Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016

Imagem de Miniatura
Arquivos
art_COWAN_Global_Burden_of_Multiple_Myeloma_ASystematic_Analysis_for_2018.PDF (16.56 MB)
Citações na Scopus
374
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER MEDICAL ASSOC
Autores
COWAN, Andrew J.
ALLEN, Christine
BARAC, Aleksandra
BASALEEM, Huda
CURADO, Maria Paula
FOREMAN, Kyle
GUPTA, Rahul
HARVEY, James
HOSGOOD, H. Dean
Citação
JAMA ONCOLOGY, v.4, n.9, p.1221-1227, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
INTRODUCTION Multiplemyeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden of MM is needed to help direct health policy, resource allocation, research, and patient care. OBJECTIVE To describe the burden of MM and the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016. DESIGN AND SETTING We report incidence, mortality, and disability-adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study. Data sources include vital registration system, cancer registry, drug availability, and survey data for stem cell transplant rates. We analyzed the contribution of aging, population growth, and changes in incidence rates to the overall change in incident cases from 1990 to 2016 globally, by sociodemographic index (SDI) and by region. We collected data on approval of lenalidomide and bortezomib worldwide. MAIN OUTCOMES AND MEASURES Multiplemyeloma mortality; incidence; years lived with disabilities; years of life lost; and DALYs by age, sex, country, and year. RESULTS Worldwide in 2016 there were 138 509 (95% uncertainty interval [UI], 121 000-155 480) incident cases of MM with an age-standardized incidence rate (ASIR) of 2.1 per 100 000 persons (95% UI, 1.8-2.3). Incident cases from 1990 to 2016 increased by 126% globally and by 106% to 192% for all SDI quintiles. The 3 world regions with the highest ASIR of MM were Australasia, North America, andWestern Europe. Multiplemyeloma caused 2.1 million (95% UI, 1.9-2.3 million) DALYs globally in 2016. Stem cell transplantation is routinely available in higher-income countries but is lacking in sub-Saharan Africa and parts of the Middle East. In 2016, lenalidomide and bortezomib had been approved in 73 and 103 countries, respectively. CONCLUSIONS AND RELEVANCE Incidence of MM is highly variable among countries but has increased uniformly since 1990, with the largest increase in middle and low-middle SDI countries. Access to effective care is very limited in many countries of low socioeconomic development, particularly in sub-Saharan Africa. Global health policy priorities forMMare to improve diagnostic and treatment capacity in low and middle income countries and to ensure affordability of effective medications for every patient. Research priorities are to elucidate underlying etiological factors explaining the heterogeneity inmyeloma incidence.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/29827
Referências
  1. Attal M, 2017, NEW ENGL J MED, V376, P1311, DOI 10.1056/NEJMoa1611750
  2. Australian Public Assessment Report for Lenalidomide, 2016, AUSTR PUBL ASS REP L
  3. Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
  4. Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735
  5. Fleming KA, 2017, AM J CLIN PATHOL, V147, P15, DOI [10.1093/AJCP/AQW143, 10.1093/ajcp/aqw143]
  6. Fonseca R, 2017, LEUKEMIA, V31, P1915, DOI 10.1038/leu.2016.380
  7. Foreman KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1
  8. Goldstein DA, 2017, ONCOTARGET, V8, P71548, DOI 10.18632/oncotarget.17742
  9. Gratwohl A, 2015, LANCET HAEMATOL, V2, pE91, DOI 10.1016/S2352-3026(15)00028-9
  10. Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X
  11. Howlader N, 1975, SEER CANC STAT REV
  12. Konstantinopoulos PA, 2006, J NATL MED ASSOC, V98, P1860
  13. Landgren O, 2006, BLOOD, V107, P904, DOI 10.1182/blood-2005-08-3449
  14. McCarthy PL, 2017, J CLIN ONCOL, V35, P3279, DOI 10.1200/JCO.2017.72.6679
  15. McNeil DG Jr, NY TIMES
  16. Miranda-Filho Adalberto, 2018, Lancet Haematol, V5, pe14, DOI 10.1016/S2352-3026(17)30232-6
  17. Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
  18. Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
  19. Neal RD, 2014, BRIT J CANCER, V110, P584, DOI 10.1038/bjc.2013.791
  20. Nwabuko OC, 2017, CANCER MANAG RES, V9, P189, DOI 10.2147/CMAR.S126136
  21. Omoti Caroline Edijana, 2007, J Pak Med Assoc, V57, P341
  22. Perrotta C, 2012, J OCCUP MED TOXICOL, V7, DOI 10.1186/1745-6673-7-25
  23. Rajkumar SV, 2016, AM J HEMATOL, V91, P720, DOI 10.1002/ajh.24402
  24. Raju GK, 2018, CLIN PHARMACOL THER, V103, P67, DOI 10.1002/cpt.871
  25. SEER* Stat Database: Incidence, 1969, SEER STAT DAT INC
  26. Sustainable Development Goals, SUST DEV GOALS
  27. Tan D, 2013, LANCET ONCOL, V14, pE571, DOI 10.1016/S1470-2045(13)70404-2
  28. Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2
  29. Wei X, 2018, CANC RES

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - ODS/03